Novelos Therapeutics, Inc. (NVLT) Develops CLR1502 (GLOW2) for Tumor Marking and Imaging
Most cancer patients will have some type of surgery. In fact, in 2011, approximately 1.3 million cancer patients were diagnosed with solid tumors in the U.S. alone. The need for surgery makes it imperative that doctors have an effective way to mark the outline of tumors. However, the present state of medical technology is unable to do so. According to Dr. Sharon Weber, Professor and Chief of Surgical Oncology, Vice Chair of Academic Affairs for General Surgery, University of Wisconsin Department of Surgery, and Director of Surgical Oncology, Carbone Cancer Center, “Current imaging modalities are extremely limited in their ability…